 |
[Alpha Biz=(Chicago) Reporter Paul Lee] Medytox announced on the 3rd that it has established a local corporation called "Luvantas" to speed up its entry into the U.S.
Medytox has applied for permission from the U.S. Food and Drug Administration (FDA) for the non-animal liquid toxin drug "MT10109L" and is speeding up its entry into the global market.
Luvantas will be 100% owned by Medytox and will be responsible for local sales and marketing of MT10109L, a toxin drug, in the United States and Canada.
Thomas Albright from Allergan was hired as Luvantas CEO. He successfully led the global launch of Botox for beauty purposes and served as Botox's global marketing strategy director.
Medytox expects Thomas Albright, who is well versed in the global skin beauty treatment market, to lead MT10109L's successful entry into the US, which aims to be approved in 2025, by establishing a customized direct sales system in the US and establishing an effective marketing strategy.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
